Indeed, GLP-1RAs have evolved over time such that the frequency of dosing has decreased from twice-daily (exenatide, BD) [65], to once-daily (liraglutide, lixisenatide) [66, 67] to once-weekly (dulaglutide, exenatide QW, semaglutide) [5, 6], suggesting a higher adherence potential for the longer-acting agents (Table 2)
This effect may matter more for the pill because of the stricter dosing rules
High doses of flavonoids can cause nausea, headaches, tingling in the limbs, or liver toxicity in some people because it is recommended not to take it during pregnancy, and breastfeeding is not established safety in these conditions
Patients with a personal or family history of migraines may experience more pronounced headache symptoms during the initiation phase